Shah Capital Management has withdrawn a proxy campaign against the re-election of directors at vaccines firm Novavax in the wake of its $1.2 billion alliance with Sanofi.
Shah Capital has stepped up its campaign for change at vaccine producer Novavax, lobbying against the re-election of three directors and executive pay packages in a letter
Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors
As the financial markets have been roiled by inflation and a minor banking crisis, the pharma industry experienced a period where M&A largely disappeared and investment into biotechs dr
Bayer chief executive Werner Baumann has been under fire from investors since he spearheaded the acquisition of agrochemical company Monsanto for $63 billion, exposing the group to multibil
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
